Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 13;33(3):568–576. doi: 10.1111/jdv.15292

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

PASI (a) and sPGA (b) response rates using NRI in relapsed and retreated patients. Patients were treated with 80 mg ixekizumab every 2 weeks up to Week 12, and then 80 mg ixekizumab every 4 weeks up to Week 52. At Week 52, responders (PASI75) were withdrawn from treatment. At relapse (PASI ≤50), patients were retreated with 80 mg ixekizumab every 4 weeks. Relapse Week 0 includes all relapse patients, regardless of the week in which the relapse occurred. NRI, non‐responder imputation; PASI75/90/100, ≥75%/≥90%/100% improvement in Psoriasis Area Severity Index; sPGA, Static Physician Global Assessment.